eShowcase: Clinical Trial Analysis
Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Safety issues pinpointed earlier with Spotfire's interactive analysis data solution
Spotfire's (Somerville, MA) Clinical Trial Analysis software is built on its DXP enterprise analytics platform for pharmaceutical companies and can be used by physicians, scientists, analysts, and nontechnical staff to discover data relationships related to drug safety and efficacy. This allows companies to address drug design and discovery earlier in the process.
Spotfire Clinical Trial Analysis provides querying capabilities of clinical and molecular data using graphs and charts. It analyzes data from various sources to identify trends, outliers, and exceptions; offers visual representations (charts, plots, graphs) of adverse event data, lab safety, demographics, and concomitant medications; allows for ad hoc data query; finds correlations between gene or protein expressions and safety profiles; and adapts to new technologies and methodologies.
Spotfire, (617) 702-1600, www.spotfire.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
